Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20761951 | 0.93 | HRH3 (0.42) | HRH3KCNH2MAPTCYP1A2MAPK1 | |
| SCHEMBL3219504 | 0.89 | HRH3 (0.48) | HRH3KCNH2MAPTCYP1A2MAPK1 | |
| SCHEMBL3910278 | 0.87 | HRH3 (0.52) | HRH3KCNH2MAPTCYP1A2MAPK1 | |
| SCHEMBL13974361 | 0.84 | HRH3 (0.37) | HRH3KCNH2MAPTL3MBTL1LOX | |
| SCHEMBL20762021 | 0.82 | KEAP1 (0.53) | HRH3SMN1; SMN2 | |
| SCHEMBL1830508 | 0.80 | SMN1; SMN2 (0.52) | HRH3SMN1; SMN2 | |
| SCHEMBL2183875 | 0.80 | SMN1; SMN2 (0.52) | HRH3SMN1; SMN2 | |
| SCHEMBL3218443 | 0.79 | L3MBTL1 (0.41) | HRH3KCNH2MAPTL3MBTL1LOX | |
| SCHEMBL2485662 | 0.77 | L3MBTL1 (0.45) | HRH3KCNH2MAPTCYP1A2MAPK1 | |
| SCHEMBL3903913 | 0.77 | PAOX (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-10-22 | — | — | US | disclosed |
| CN-111107903-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019034696-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | HRH3 499/4885KCNH2 784/4885MAPT 3848/4885 |
| US-20200331850-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | HRH3 639/4885KCNH2 815/4885MAPT 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.